Degrading the Undruggable: A New Paradigm for Targeting KRAS

• Mechanism of Action of a Novel KRAS G12d Targeted Protein Degrader: Setidegrasib
• Clinical Overview: Efficacy and Safety in PDAC, NSCLC and other solid tumors
• Future Directions 

Speakers:

Stephanie Braun

Executive Medical Director

Astellas Pharma